Page contents Back to list Full notification Final report General information GMO characterization European Commission administrative Information Return to search
Full notification Final report - General information Notification Number B/DE/22/PEI4772 Member State to which the notification was sent Germany Date of acknowledgement from the Member State Competent Authority 11/01/2022 Title of the Project YTB323 – Phase 1, open label, multicenter dose escalation study of YTB323 in adult patients with CLL/SLL, DLBCL and ALL Proposed period of release: 15/06/2020 to 30/10/2025 Name of the Institute(s) or Company(ies) Novartis Pharma AG, Postfach, 4002 Basel, Switzerland
Is the same GMO been notified elsewhere by the same notifier? Yes:
Austria; Germany; Spain; France; Italy;
Has the same GMO been notified elsewhere by the same notifier? No GMO characterization GMO is a: Other Identity of the GMO: Autologous T cells transduced with a replication-deficient HIV-1 derived viral vector to express a chimeric (murine/human) antigen receptor (CAR).  Information relating to the recipient or parental organisms from which the GMO is derived Common Name: Human Genus: Homo Species: Homo Sapiens Subspecies: Strain: Pathovar: European Commission administrative Information Consent given by the Member State Competent Authority: Not known
Close
Select your language
English